Adalimumab Treatment in Children with Refractory Crohn’s Disease

被引：0
作者：
Yoram Rosenbach
Corina Hartman
Rivka Shapiro
Akiva Hirsch
Yaron Avitzur
Raanan Shamir
机构：
[1] Tel-Aviv University,Institute of Gastroenterology, Nutrition, and Liver Disease, Schneider Children’s Medical Center of Israel, Sackler Faculty of Medicine
来源：
Digestive Diseases and Sciences | 2010年 / 55卷
关键词：
Crohn’s disease; Adalimumab; Infliximab; Children;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Information on safety and efficacy of adalimumab in children with Crohn’s disease (CD) is limited. We present a case-series of 14 children with severe CD treated with adalimumab during a 3.5-year period. Fourteen children (nine boys, five girls), aged 13.9 years (range 1.9–19.1) were treated with adalimumab during 12.5 months (range 7–42). All had steroid or immunosuppression-drugs refractory disease. Ten patients (71%) had been previously treated with infliximab, 13/14 were treated with different immunosuppressive drugs and all were steroid-dependent or resistant. Seven children (50%) showed full clinical response and 5/14 (35%) improved partially. Two children (15%) had loss of response after a period of transient improvement. Adalimumab treatment enabled complete steroids withdrawal in 8/14 (57%) of steroid-dependent children. Currently, five children are in complete remission with adalimumab monotherapy for a median 14 months (range 9–24). Adalimumab may induce and maintain remission in children with severe, refractory CD. Prospective safety and efficacy confirmation of this data in children is necessary.
引用
收藏
页码：747 / 753
页数：6
相关论文
共 111 条
[11]  
Griffiths A(2007)Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial Gastroenterology 132 52-65
[12]  
Olson A(2007)Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829-838
[13]  
Johanns J(2007)Adalimumab in patients with Crohn’s disease—safety and efficacy in an open-label single centre study Aliment Pharmacol Ther 25 787-796
[14]  
Liu G(2007)Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study Aliment Pharmacol Ther 25 675-680
[15]  
Travers S(2008)The use of adalimumab in the management of refractory Crohn’s disease Aliment Pharmacol Ther 27 308-315
[16]  
Heuschkel R(2008)Adalimumab induces and maintains remission in severe, resistant paediatric Crohn's disease J Pediatr Gastroenterol Nutr 46 208-211
[17]  
Markowitz J(2005)Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn’s disease J Pediatr Gastroenterol Nutr 41 357-359
[18]  
Cohen S(2007)Spanish scientific group on Crohn’s disease and ulcerative colitis. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial Aliment Pharmacol Ther 25 409-418
[19]  
Winter H(undefined)undefined undefined undefined undefined-undefined
[20]  
Veereman-Wauters G(undefined)undefined undefined undefined undefined-undefined
12345678910